Subutinib Maleate

马来酸舒布替尼

Report date: 2022/09/23 20:01:17
NME

Base Information

Drug NameSubutinib Maleate
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor antagonistsStem cell growth factor receptor inhibitorsPlatelet-derived growth factor receptor beta inhibitors
TargetsStem cell growth factor receptorPlatelet-derived growth factor receptor betaVascular endothelial growth factor receptor
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesChina State Institute of Pharmaceutical Industry Co LtdJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesState Pharmaceutical Administration of Shanghai Institute of Pharmaceutical IndustryJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A